Zydus Cadila gets USFDA nod for Hydroxychloroquine Sulfate tablets

Mumbai, Sep 25 (UNI) Cadila Healthcare Ltd has received an approval from the US FDA for Hydroxychloroquine Sulfate Tablets in the strength of 200 mg.

The drug falls in the DMARD (Disease Modifying Anti-Rheumatic Drug) segment and is used in the management of rheumatoid arthritis.

The sales of Hydroxychloroquine Sulfate Tablets in the US market in 2006 as per NDC Health was estimated at USD Dollar 30 mn, Zydus said in a communication to the Bombay Stock Exchange (BSE) today.

The Company will market the drug through its US subsidiary Zydus Pharmaceuticals (USA) Inc. The group has 27 approvals since the commencement of filing process in FY 2003-04. So far, the group has filed 65 ANDAs and 55 DMFs, Zydus said.

UNI